bioMérieux, a world leader in the field of in vitro diagnostics, has signed an agreement to acquire AES Laboratoire, a leading French group, specialized in industrial microbiological control, for 183 million euros. This will be bioMérieux’s ninth acquisition in five years and its third in the area of industrial applications.
FDA Clears First Test for Recent Infection with Toxoplasmosis Parasite
On May 18, the U.S. Food and Drug Administration cleared the first test to help determine whether a pregnant woman or a person with swollen lymph nodes testing positive for toxoplasmosis, developed the infection within the past four months.
First-Quarter 2011 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2011. Net sales for the period reached €328 million, up a reported 6.8% from €307 million in first-quarter 2010. Growth amounted to 3.5% like-for-like (at constant exchange rates and scope of consolidation).
bioMérieux Achieves 100th PREVI® ISOLA Milestone, Installing its Automated Plate Streaker at Grady Health System
Innovative system designed by microbiologists for microbiologists helps a growing number of labs achieve substantial productivity gains.
bioMérieux Results 2010
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today and approved the consolidated financial statements for the year ended December 31, 2010. The meeting was chaired by Jean-Luc Bélingard and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors will be issuing an unqualified opinion in the coming days.
Ipsen and bioMérieux Enter into a Broad Partnership in Personalized Medicine
The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care
Philips and bioMérieux Announce Milestone in the Development of Innovative Handheld Diagnostic Solutions for Rapid Point-of-Care Testing
Combination of Philips’ Magnotech technology and bioMérieux’s assay technology achieves the performance requirements of rapid diagnostic testing in point-of-care applications
bioMérieux - 2010 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2010.
bioMérieux Expands Customer Services Offer, Appointing James P. Whelan as Executive Vice President, Commercial Services
A world leader in in vitro diagnostics, bioMérieux announces the appointment of James P. Whelan as Executive Vice President of Commercial Services. In this newly created role, he will be responsible for reinforcing bioMérieux’s global service offering. This enhanced offering will include expanded customer lab audits, laboratory accreditation support and comprehensive scientific training programs.
Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis
Sepsis progresses quickly, yet rapid test is still largely unavailable in the U.S.